Alembic Pharmaceuticals today announced the first prescription-based sale of Pivya® (pivmecillinam) tablets, an oral prescription antibiotic, following its recent commercial launch in the United States of America (US). Pivya® is Alembic's first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic.

Pivya® represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.

Aluwind Infra-Tech will hold a meeting of the Board of Directors of the Company on 11 March 2026.

Amarnath Securities has cancelled the board meeting which was scheduled to be held on 5 March 2026.

Angel One announced key business parameters for February 2026 as under:

Particulars	Feb'26	MoM Growth	YoY Growth
Client Base (Million)	36.93	1.5%	20.8%
Avg. Client Funding Book (Rs crore)	5933	-3.0%	46.4%
Average Daily Turnover (Rs crore)
Overall	55,74,300	-13.0%	88.4%
F&O	54,13,000	-13.3%	87.4%
Cash	7,800	-2.2%	28.3%
Commodity	1,53,500	-0.6%	135.6%

Associated Alcohols & Breweries will hold a meeting of the Board of Directors of the Company on 12 March 2026.

Avenue Supermarts has opened a new store at Ullal, Dakshina Kannada (Karnataka) today. The total number of stores as on date stands at 453.

Bajaj Electricals has allotted 2,273 equity shares under ESOP on 06 March 2026. Post this allotment, the issued, subscribed and paid-up capital of the Company shall comprise of 11,53,90,713 equity shares of Rs. 2 each fully paid-up amounting to Rs. 23,07,81,426/-.

Balmer Lawrie & Company announced that the Board of Directors of the Company at its meeting held on 5 March 2026, inter alia, have recommended the interim dividend of Rs 4.25 per equity Share (i.e. 42.5%) , subject to the approval of the shareholders.

Avio Smart Market Stack (ASMS), formerly known as Bartronics India, has initiated an expanded collaboration with Huwel Lifesciences to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India.

The development follows the recently signed Shareholders' Agreement between the two companies, under which they aim to jointly scale advanced diagnostic technologies and bring them to institutional and healthcare markets across the country.

Huwel Lifesciences has developed multiple patented diagnostic technologies and is building a strong pipeline of new products, with several additional patents and platforms currently under development. The company's capabilities span RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels. Research, assay development, and manufacturing are carried out within Huwel's own facilities.

Positioning itself as a fully indigenous diagnostics innovator, Huwel is among the few molecular diagnostics companies in India with the capability to design, develop, and manufacture most components of its diagnostic platforms in-house, aligning with the Government of India's “Make in India” initiative.

Capri Global Capital will hold a meeting of the Board of Directors of the Company on 10 March 2026.